Preventing renal transplant failure

Annals of the Academy of Medicine Singapore

Volumn 34, Issue 1, 2005, Pages 36-43

  Vathsala, A ^a  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

Calcineurin inhibitors; Chronic allograft nephropathy; Hyperfiltration; Rejection; Sirolimus

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CYCLOSPORIN A; DACLIZUMAB; HLA ANTIGEN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ANTIBODY; MYCOPHENOLIC ACID; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; CADAVER KIDNEY; CANCER; CHRONIC GRAFT REJECTION; CLINICAL TRIAL; DEATH; DRUG POTENCY; GLOMERULUS FILTRATION; GRAFT FAILURE; GRAFT SURVIVAL; HLA MATCHING; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION; INFECTION RISK; KIDNEY DONOR; KIDNEY INJURY; KIDNEY ISCHEMIA; KIDNEY TRANSPLANTATION; KIDNEY TUMOR; LIVING DONOR; NEPHROTOXICITY; RECIPIENT; REVIEW; RISK BENEFIT ANALYSIS; SENSITIZATION; SIDE EFFECT;

EID: 15044356154     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Vathsala A, Woo KT. Renal transplantation in cyclosporine-treated recipients at the Singapore General Hospital. Clin Transpl 1999:189-97.
2. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Chapman JR, Allen RD. Delta analysis of posttransplantation tubulointerstitial damage. Transplantation 2004;78:434-41.
3. Matas AJ, Gillingham KJ, Payne WD, Najarian JS. The impact of an acute rejection episode on long-term renal allograft survival (t1/2). Transplantation 1994;57:857-9.
4. Sijpkens YW, Doxiadis II, Mallat MJ, de Fijter JW, Bruijn JA, Claas FH, et al. Early versus late acute rejection episodes in renal transplantation. Transplantation 2003;75:204-8.
5. Cecka JM. The UNOS Renal Transplant Registry. Clin Transpl 2001: 1-18.
6. Hardy S, Lee SH, Terasaki PI. Sensitization 2001. Clin Transpl 2002; 271-8.
7. Perico N, Cattaneo D, Sayegh MH, Remuzzi G. Delayed graft function in kidney transplantation. Lancet 2004;364:1814-27.
8. Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000;342:605-12.
9. Margreiter R; European Tacrolimus vs Ciclosporin Microemulsion Renal Transplantation Study Group. Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study. Lancet 2002;359:741-6.
10. Cai J. A comparison of major immunosuppressive triple therapies in renal transplantation. Clin Transpl 2003:433-40.
11. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 1996;61:1029-37.
12. Mathew TH. A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation: results at three years. Transplantation 1998;65:1450-4. Erratum in: Transplantation 1998;66:817.
13. Mathew TH. A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation: results at three years. Transplantation 1998;65:1450-4. Erratum in: Transplantation 1998;66:817.
14. Ojo AO, Meier-Kriesche HU, Hanson JA, Leichtman AB, Cibrik D, Magee JC, et al. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 2000;69:2405-9.
15. Thibaudin D, Alamartine E, de Filippis JP, Diab N, Laurent B, Berthoux F. Advantage of antithymocyte globulin induction in sensitized kidney recipients: a randomized prospective study comparing induction with and without antithymocyte globulin. Nephrol Dial Transplant 1998;13:711-5.
16. Vincenti F, Kirkman R, Light S, Bumgardner G, Pescovitz M, Halloran P, et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med 1998;338:161-5.
17. Nashan B, Moore R, Amlot P, Schmidt AG, Abeywickrama K, Soulillou JP. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CH1B 201 International Study Group. Lancet 1997;350:1193-8. Erratum in: Lancet 1997;350:1484.
18. Nashan B, Moore R, Amlot P, Schmidt AG, Abeywickrama K, Soulillou JP. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CH1B 201 International Study Group. Lancet 1997;350:1193-8. Erratum in: Lancet 1997;350:1484.
19. Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. Lancet 2000;356:194-202.
20. Shoskes DA, Cecka JM. Deleterious effects of delayed graft function in cadaveric renal transplant recipients independent of acute rejection. Transplantation 1998;66:1697-701.
21. Irish WD, McCollum DA, Tesi RJ, Owen AB, Brennan DC, Bailly JE, et al. Nomogram for predicting the likelihood of delayed graft function in adult cadaveric renal transplant recipients. J Am Soc Nephrol 2003;14:2967-74.
22. Hauet T, Goujon JM, Vandewalle A. To what extent can limiting cold ischaemia/reperfusion injury prevent delayed graft function? Nephrol Dial Transplant 2001;16:1982-5.
23. Olyaei AJ, de Mattos AM, Bennett WM. Nephrotoxicity of immunosuppressive drugs: new insight and preventive strategies. Curr Opin Crit Care 2001;7:384-9.
24. Nankivell BJ, Borrows RJ, Fung CL, OConnell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med 2003;349:2326-33.
25. Mange KC, Cizman B, Joffe M, Feldman HI. Arterial hypertension and renal allograft survival. JAMA 2000;283:633-8.
26. Opelz G, Wujciak T, Ritz E. Association of chronic kidney graft failure with recipient blood pressure. Collaborative Transplant Study. Kidney Int 1998;53:217-22.
27. Paul LC, Benediktsson H. Post-transplant hypertension and chronic renal allograft failure. Kidney Int 1995;52(Suppl):S34-S37.
28. Brenner BM, Mackenzie HS. Nephron mass as a risk factor for progression of renal disease. Kidney Int 1997;63(Suppl):S124-S127.
29. Hostetter TH, Olson JL, Rennke HG, Venkatachalam MA, Brenner BM. Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. J Am Soc Nephrol 2001;12:1315-25.
30. Terasaki PI, Koyama H, Cecka JM, Gjertson DW. The hyperfiltration hypothesis in human renal transplantation. Transplantation 1994;57: 1450-4.
31. Roodnat JI, Mulder PG, Zietse R, Rischen-Vos J, van Riemsdijk IC, Ijzermans JN, et al. Cholesterol as an independent predictor of outcome after renal transplantation. Transplantation 2000;69:1704-10.
32. Fitzgerald JT, Gallay B, Taranto SE, McVicar JP, Troppmann C, Chen X, et al. Pretransplant recipient cytomegalovirus seropositivity and hemodialysis are associated with decreased renal allograft and patient survival. Transplantation 2004;77:1405-11.
33. Soderberg-Naucler C, Emery VC. Viral infections and their impact on chronic renal allograft dysfunction. Transplantation 2001;71(11 Suppl):S24-S30.
34. Nickeleit V, Hirsch HH, Zeiler M, Gudat F, Prince O, Thiel G, et al. BK-virus nephropathy in renal transplants-tubular necrosis, MHC-class II expression and rejection in a puzzling game. Nephrol Dial Transplant 2000;15:324-32.
35. Gallagher MP, Hall B, Craig J, Berry G, Tiller DJ, Eris J; Australian Multicenter Trial of Cyclosporine Withdrawal Study Group and the ANZ Dialysis and Transplantation Registry. A randomized controlled trial of cyclosporine withdrawal in renal-transplant recipients: 15-year results. Transplantation 2004;78:1653-60.
36. Smak Gregoor PJ, de Sevaux RG, Ligtenberg G, Hoitsma AJ, Hene RJ, Weimar W, et al. Withdrawal of cyclosporine or prednisone six months after kidney transplantation in patients on triple drug therapy: a randomized, prospective, multicenter study. J Am Soc Nephrol 2002;13:1365-73.
37. Weir MR, Ward MT, Blahut SA, Klassen DK, Cangro CB, Bartlett ST, et al. Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy. Kidney Int 2001;59: 1567-73.
38. Citterio F, Scata MC, Violi P, Romagnoli J, Pozzetto U, Nanni G, et al. Rapid conversion to sirolimus for chronic progressive deterioration of the renal function in kidney allograft recipients. Transplant Proc 2003;35:1292-4.
39. Flechner SM, Goldfarb D, Modlin C, Feng J, Krishnamurthi V, Mastroianni B, et al. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 2002;74:1070-6.
40. Campistol JM, Inigo P, Larios S, Bescos M, Oppenheimer F. Role of transforming growth factor-beta 1 in the progression of chronic allograft nephropathy. Nephrol Dial Transplant 2001;16(Suppl 1):114-6.
41. Kagami S, Border WA, Miller DE, Noble NA. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest 1994;93:2431-7.
42. Jardine AG, Holdaas H, Fellstrom B, Cole E, Nyberg G, Gronhagen-Riska C, et al; ALERT Study Investigators. Fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: post-hoc subgroup analyses of the ALERT Study. Am J Transplant 2004;4: 988-95.
43. Fellstrom B, Holdaas H, Jardine AG, Holme I, Nyberg G, Fauchald P, et al; Assessment of Lescol in Renal Transplantation Study Investigators. Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial. Kidney Int 2004;66:1549-55.
44. Katznelson S, Wilkinson AH, Kobashigawa JA, Wang XM, Chia D, Ozawa M, et al. The effect of pravastatin on acute rejection after kidney transplantation - a pilot study. Transplantation 1996;61:1469-74.
45. Ramos E, Drachenberg CB, Papadimitriou JC, Hamze O, Fink JC, Klassen DK, et al. Clinical course of polyoma virus nephropathy in 67 renal transplant patients. J Am Soc Nephrol 2002;13:2145-51.
46. Hariharan S, Adams MB, Brennan DC, Davis CL, First MR, Johnson CP, et al. Recurrent and denovo glomerular disease after renal transplantation: a report from Renal Allograft Disease Registry (RADR). Transplantation 1999;68:635-41.
47. Bhalla V, Nast CC, Stollenwerk N, Tran S, Barba L, Kamil ES, et al. Recurrent and de novo diabetic nephropathy in renal allografts. Transplantation 2003;75:66-71.